Concepedia

CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

Sadhna Vora, Dejan Juric, Nayoon Kim, Mari Mino–Kenudson, Tiffany G. Huynh, Carlotta Costa, Elizabeth L. Lockerman, Sarah F. Pollack, Manway Liu, Xiaoyan Li,

Cancer Cell · 2014 · 439 citations · 35 references

DOIFull text

Open access

Concepts

References

35

The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity

Jordi Barretina, Giordano Caponigro, Nicolas Stransky et al. · Nature · 2012 · 8.5K citations

, , +15

Synergistic drug combinations tend to improve therapeutically relevant selectivity

Joseph Lehár, Andrew Krueger, William Avery et al. · Nature Biotechnology · 2009 · 957 citations · Full text

, , +13

mTOR complex 2 (mTORC2) controls hydrophobic motif phosphorylation and activation of serum- and glucocorticoid-induced protein kinase 1 (SGK1)

Juan Manuel García‐Martínez, Dario R. Alessi · Biochemical Journal · 2008 · 891 citations · Full text

, , +14

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

Johanna C. Bendell, Jordi Rodón, Howard A. Burris et al. · Journal of Clinical Oncology · 2011 · 686 citations · Full text

, , +14

The PIK3CA gene is mutated with high frequency in human breast cancers

Kurtis E. Bachman, Pedram Argani, Yardena Samuels et al. · Cancer Biology & Therapy · 2004 · 664 citations · Full text

, , +17